- Author: Lawrence C Wolfe, MD; Chief Editor: George T Griffing, MD more...
Glucose 6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic disorder of red blood cells, affecting 400 million people worldwide. Paul Carlson and colleagues first reported G6PD deficiency in 1956 while working on a patient previously identified as "primaquine sensitive."
G6PD is an enzyme involved in the pentose monophosphate pathway. G6PD deficiency leads to free radical mediated oxidative damage to red blood cells, which in turn causes hemolysis. It is an X-linked disorder with high prevalence particularly in people of African, Asian, and Mediterranean descent. G6PD deficiency is polymorphic, with more than 400 variants.
Patients with G6PD-deficient alleles have selective advantage against severe malaria, hence it is highly prevalent in populations where malaria is endemic.
The clinical presentation of glucose 6- phosphate dehydrogenase (G6PD) deficiency includes a spectrum of hemolytic anemia ranging from mild to severe hemolysis in response to oxidative stress. The likelihood of developing hemolysis and its severity depends on the level of the enzyme deficiency, which in turn depends on the G6PD variant.[3, 4]
The G6PD enzyme catalyzes the oxidation of glucose-6-phosphate and the reduction of nicotinamide adenine dinucleotide phosphate (NADP+) to nicotinamide adenine dinucleotide phosphate (NADPH) in the pentose monophosphate shunt. NADPH is important in maintaining glutathione in its reduced form, which protects the red blood cell against oxidative stress.
Red blood cells carry oxygen and hence are more susceptible to oxidative stress than other cells. The pentose monophosphate shunt is the only means of NADPH generation in red blood cells and therefore crucial in protecting red cells against oxidative damage.
In a G6PD deficient patient, oxidative stresses can denature hemoglobin and cause intravascular hemolysis.
Drugs, chemical agents, infections, ingestion of fava beans, or ketoacidosis can trigger oxidative stress leading to hemolysis.
Jaundice in G6PD-deficient neonates is considered to be due to an imbalance between the production and conjugation of bilirubin, with a tendency towards inefficient bilirubin conjugation. Premature infants are at special risk of the bilirubin production-conjugation imbalance.
G6PD deficiency is prevalent worldwide. In the United States, African Americans are primarily affected, with a prevalence of about 10%; however it is also seen among Italians (especially Sardinian ancestry), Greeks, Turks, South East Asians, people of Asian ancestry, and Sephardic Jews.
Internationally, the geographic prevalence of the disorder correlates with the distribution of malaria. The highest prevalence rates (with gene frequencies from 5-25%) are found in the following regions:
The Middle East
Tropical and subtropical Asia
Some areas of the Mediterranean
Papua New Guinea
The heterogeneity of polymorphic G6PD variants is proof of their independent origin, and it supports the notion that they have been selected by a common environmental agent, in keeping with the concept of convergent evolution.
G6PD deficiency affects all races, although the severity of G6PD deficiency varies significantly among racial groups. The highest prevalence is among the people of African, Asian, or Mediterranean descent. Variants producing severe deficiency primarily occur in the Mediterranean population. African populations have milder hemolysis due to higher enzyme levels.
G6PD deficiency is an X-linked inherited disease that primarily affects men. Women may be affected if they are homozygous, which occurs in populations in which the frequency of G6PD deficiency is quite high. Heterozygous women (carriers) can experience clinical disease as a result of X chromosome inactivation, gene mosaicism, or hemizygosity.
Many people with G6PD deficiency are asymptomatic. However, case reports of acute massive hemolysis with jaundice have been reported especially in the neonatal period, leading to kernicterus and fatality.[6, 7, 8, 9, 10]
Kernicterus or bilirubin encephalopathy is a rare complication of neonatal jaundice complicated by G6PD deficiency. Kernicterus, although infrequent, has about 10% mortality and 70% long-term morbidity usually evident in infants with a bilirubin level higher than 20 mg/dL.
Massive hemolysis complicating G6PD deficiency has also been reported in patients with hepatitis infections, specifically hepatitis A and E in the Indian subcontinent.
The X linked pattern of inheritance of G6PD deficiency and its clinical severity should be discussed with parents and counseling with regard to their risk for having other children should be provided, especially in populations in which G6PD deficiency is highly prevalent.
If a mother is a heterozygote, the chances of recurrence is 50% with every subsequent male pregnancy.
Parental-child G6PD deficiency self-care discussions are associated with better child health, and parental involvement in these discussions is facilitated by the thoroughness and clarity of patient education received from provider.
Additional resources are available at G6PD Deficiency Association - Favism.
Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009 May-Jun. 42 (3):267-78. [Medline].
Alving AS, Carson PE, Flanagan CL, Ickes CE. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956 Sep 14. 124 (3220):484-5. [Medline].
Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008 Jan 5. 371 (9606):64-74. [Medline].
Mason PJ, Bautista JM, Gilsanz F. G6PD deficiency: the genotype-phenotype association. Blood Rev. 2007 Sep. 21 (5):267-83. [Medline].
Kaplan M, Hammerman C. The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective. J Perinatol. 2009 Feb. 29 Suppl 1:S46-52. [Medline].
Weng YH, Chiu YW. Clinical characteristics of G6PD deficiency in infants with marked hyperbilirubinemia. J Pediatr Hematol Oncol. 2010 Jan. 32 (1):11-4. [Medline].
Dhillon AS, Darbyshire PJ, Williams MD, Bissenden JG. Massive acute hemolysis in neonates with glucose-6-phosphate dehydrogenase deficiency. Arch Dis Child Fetal Neonatal Ed. 2003. 88:F534-F536 doi:10.1136/fn.88.6.F534.
Valaes T. Severe neonatal jaundice associated with glucose-6-phosphate dehydrogenase deficiency: pathogenesis and global epidemiology. Acta Paediatr Suppl. 1994 Mar. 394:58-76. [Medline].
Kaplan M, Hammerman C. Severe neonatal hyperbilirubinemia. A potential complication of glucose-6-phosphate dehydrogenase deficiency. Clin Perinatol. 1998 Sep. 25 (3):575-90, viii. [Medline].
Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase deficiency: a hidden risk for kernicterus. Semin Perinatol. 2004 Oct. 28 (5):356-64. [Medline].
American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004 Jul. 114 (1):297-316. [Medline].
Abid S, Khan AH. Severe hemolysis and renal failure in glucose-6-phosphate dehydrogenase deficient patients with hepatitis E. Am J Gastroenterol. 2002 Jun. 97 (6):1544-7. [Medline].
Guan Y, Roter DL, Huang A, Erby LA, Chien YH, Hwu WL. Parental discussion of G6PD deficiency and child health: implications for clinical practice. Arch Dis Child. 2014 Mar. 99 (3):251-5. [Medline].
Luzzatto L, Poggi V. Glucose-6-phosphate dehydrogenase deficiency. Orskin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux SE, eds. Nathan & Oski's Hematology of Infancy and Childhood. 7th ed. Philadelphia PA: Saunders; 2009. 883-907.
Vulliamy TJ, Luzzato L. Glucose-6-phosphatase dehydrogenase deficiency and related disorders. Blood Principles and Practice of Hematology. 2nd ed. 2002.
Luzzatto L. Hemolytic anemia and anemia due to blood loss. Harrison’s Principles of Internal Medicine. 18th ed. McGraw-Hill Professional Publishing; 2011.
Kuzniewicz MW, Wickremasinghe AC, Wu YW, McCulloch CE, Walsh EM, Wi S, et al. Incidence, etiology, and outcomes of hazardous hyperbilirubinemia in newborns. Pediatrics. 2014 Sep. 134 (3):504-9. [Medline].
Makarona K, Caputo VS, Costa JR, et al. Transcriptional and epigenetic basis for restoration of G6PD enzymatic activity in human G6PD-deficient cells. Blood. 2014 Jul 3. 124 (1):134-41. [Medline].
Bautista JM. Epigenetic therapy reprograms hereditary disease. Blood. 2014 Jul 3. 124 (1):7-8. [Medline].
Gomez-Gallego F, Garrido-Pertierra A, Bautista JM. Structural defects underlying protein dysfunction in human glucose-6-phosphate dehydrogenase A(-) deficiency. J Biol Chem. 2000 Mar 31. 275 (13):9256-62. [Medline].
Oppenheim A, Jury CL, Rund D, Vulliamy TJ, Luzzatto L. G6PD Mediterranean accounts for the high prevalence of G6PD deficiency in Kurdish Jews. Hum Genet. 1993 Apr. 91 (3):293-4. [Medline].
Cappellini MD, Martinez di Montemuros F, De Bellis G, Debernardi S, Dotti C, Fiorelli G. Multiple G6PD mutations are associated with a clinical and biochemical phenotype similar to that of G6PD Mediterranean. Blood. 1996 May 1. 87 (9):3953-8. [Medline].
Martinez di Montemuros F, Dotti C, Tavazzi D, Fiorelli G, Cappellini MD. Molecular heterogeneity of glucose-6-phosphate dehydrogenase (G6PD) variants in Italy. Haematologica. 1997 Jul-Aug. 82 (4):440-5. [Medline].
Cappellini MD, Sampietro M, Toniolo D, Carandina G, Martinez di Montemuros F, Tavazzi D, et al. G6PD Ferrara I has the same two mutations as G6PD A(-) but a distinct biochemical phenotype. Hum Genet. 1994 Feb. 93 (2):139-42. [Medline].
Pinto FM, Gonzalez AM, Hernandez M, Larruga JM, Cabrera VM. Sub-Saharan influence on the Canary Islands population deduced from G6PD gene sequence analysis. Hum Biol. 1996 Aug. 68 (4):517-22. [Medline].
Beutler E, Kuhl W, Vives-Corrons JL, Prchal JT. Molecular heterogeneity of glucose-6-phosphate dehydrogenase A-. Blood. 1989 Nov 15. 74 (7):2550-5. [Medline].
Kurdi-Haidar B, Mason PJ, Berrebi A, Ankra-Badu G, al-Ali A, Oppenheim A, et al. Origin and spread of the glucose-6-phosphate dehydrogenase variant (G6PD-Mediterranean) in the Middle East. Am J Hum Genet. 1990 Dec. 47 (6):1013-9. [Medline].
Karimi M, Martinez di Montemuros F, Danielli MG, Farjadian S, Afrasiabi A, Fiorelli G, et al. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Fars province of Iran. Haematologica. 2003 Mar. 88 (3):346-7. [Medline].
Betke K, Beutler E, Brewer GJ, et al. Standardization of procedures for the study of glucose-6-phosphate dehydrogenase: report of a WHO Scientific Group. World Health Organ Tech Rep Ser. 1967. 366:1-53.
Minucci A, Giardina B, Zuppi C, Capoluongo E. Glucose-6-phosphate dehydrogenase laboratory assay: How, when, and why?. IUBMB Life. 2009 Jan. 61 (1):27-34. [Medline].
Shah SS, Diakite SA, Traore K, Diakite M, Kwiatkowski DP, Rockett KA, et al. A novel cytofluorometric assay for the detection and quantification of glucose-6-phosphate dehydrogenase deficiency. Sci Rep. 2012. 2:299. [Medline].
Domingo GJ, Satyagraha AW, Anvikar A, et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J. 2013 Nov 4. 12:391. [Medline].
Au WY, Ngai CW, Chan WM, Leung RY, Chan SC. Hemolysis and methemoglobinemia due to hepatitis E virus infection in patient with G6PD deficiency. Ann Hematol. 2011 Oct. 90 (10):1237-8. [Medline].